HOWL Projected Dividend Yield
Werewolf Therapeutics Inc ( NASDAQ : HOWL )Werewolf Therapeutics is a biopharmaceutical company, engaged in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. Co. is utilizing its proprietary PREDATOR platform to design molecules that stimulate both adaptive and innate immunity with the aim of addressing the limitations of conventional proinflammatory immune therapies. Co.'s molecules, which it refers to as INDUKINE molecules, are intended to activate selectively in the tumor microenvironment. Co.'s product candidates, WTX-124 and WTX-330, are delivered, activated Interleukin-2 and Interleukin-12, respectively, INDUKINE molecules for the treatment of solid tumors. 20 YEAR PERFORMANCE RESULTS |
HOWL Dividend History Detail HOWL Dividend News HOWL Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |